spironolactone has been researched along with Parkinson Disease in 5 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "86), and chronic use of spironolactone (OR, 2." | 1.37 | Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. ( Bastuji-Garin, S; Bedane, C; Bernard, P; Delaporte, E; Dutronc, Y; Guillaume, JC; Ingen-Housz-Oro, S; Joly, P; Lemordant, P; Maillard, H; Pauwels, C; Picard-Dahan, C; Richard, MA; Roujeau, JC; Sparsa, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, C | 1 |
| Kumar, R | 1 |
| Bastuji-Garin, S | 1 |
| Joly, P | 1 |
| Lemordant, P | 1 |
| Sparsa, A | 1 |
| Bedane, C | 1 |
| Delaporte, E | 1 |
| Roujeau, JC | 1 |
| Bernard, P | 1 |
| Guillaume, JC | 1 |
| Ingen-Housz-Oro, S | 1 |
| Maillard, H | 1 |
| Pauwels, C | 1 |
| Picard-Dahan, C | 1 |
| Dutronc, Y | 1 |
| Richard, MA | 1 |
| Teive, HA | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Karimova, MKh | 2 |
| Vartanian, KZ | 2 |
| Petelin, LS | 1 |
| Kubatiev, AA | 1 |
1 trial available for spironolactone and Parkinson Disease
| Article | Year |
|---|---|
[Effect of veroshpiron on hormone level in patients with Parkinson's disease].
Topics: Adrenal Cortex Hormones; Adult; Aged; Aldosterone; Humans; Middle Aged; Parkinson Disease; Spironola | 1994 |
4 other studies available for spironolactone and Parkinson Disease
| Article | Year |
|---|---|
The effect of estrogen in a man with Parkinson's disease and a review of its therapeutic potential.
Topics: Antiparkinson Agents; Drug Implants; Estrogens; Feminization; Gender Identity; Humans; Levodopa; Mal | 2013 |
Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Bed Rest; Bipolar Disorder; Case-Control Studies; Cog | 2011 |
Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure.
Topics: Aged; Gynecomastia; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Movement Di | 2007 |
[Experience using veroshpiron in the combined therapy of parkinsonism].
Topics: Adrenal Glands; Adult; Aged; Antiparkinson Agents; Catecholamines; Drug Evaluation; Drug Therapy, Co | 1988 |